Belgian Combo Therapy Halves Type 1 Diabetes Risk in Study
Belgian researchers from VUB and KU Leuven show a combination therapy targeting both immunity and beta cells halves type 1 diabetes risk in mice.
Tag
5 articles
Belgian researchers from VUB and KU Leuven show a combination therapy targeting both immunity and beta cells halves type 1 diabetes risk in mice.
VUB and KU Leuven researchers show combining immunotherapy with beta cell protection significantly slows type 1 diabetes in preclinical trials.
Moderna and Merck's mRNA vaccine reduced melanoma recurrence risk by 49% over five years, offering new hope for advanced skin cancer patients.
A personalized mRNA cancer vaccine from Moderna and Merck reduced melanoma recurrence risk by 49% over five years, marking a major advance.
A personalized mRNA cancer vaccine combined with Keytruda reduced melanoma recurrence risk by 49% over five years, according to new clinical trial data.